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Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder of elderly people. Cardiac
dysfunction is a marker of grim prognosis in MDS. We evaluated cardiac dysfunction of MDS patients with or
without transfusion dependency by tissue doppler echocardiography. We found the average values of ventricular
end-systolic and end-diastolic volumes in transfusion dependency MDS group higher than others. These results
were strongly correlated to hemoglobin levels. Tissue Doppler Echocardiography should be routinely performed
in MDS patients to detect preclinical cardiac alterations and prevent more heart insults in this group of chronic
anemic aged patients.
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Myelodysplastic syndrome (MDS) is a clonal hema-
topoietic stem cell disorder and anemia with transfusion
dependency is detected in up to 60% of patients [1].
Early recognition of patients at risk of heart failure is dif-
ficult because global ventricular function and exercise
capacity in chronically transfused patients may remain
normal until late in the disease [2].
We evaluated three groups of MDS patients: cases with
transfusion dependency (T-MDS), patients without
transfusion dependency (NT-MDS) and age-matched
controls. Transfusion dependency was considered as
reported by Malcovati et al. [3]. Echo-Doppler, tissue vel-
ocity imaging and strain measures were obtained using
General Electric-Healthcare (GE, Vivid-7) system with a
matrix probe M3S.
Parametric data were analyzed by “one-way” analyzes of
variance (ANOVA) with Bonferroni’s Multiple Comparison* Correspondence: ronaldpinheiro@pq.cnpq.br
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reproduction in any medium, provided the oras a post-test. Non-parametric data were analyzed by
Kruskal-Wallis. The studies of correlation was assessed by
Pearson’s correlation coefficient (r).
The three groups were composed of 13 T-MDS, 21 NT-
MDS and 14 controls. There were no significant differences
between groups. See Table 1. Table 2 presents the echocar-
diographic parameters. The average values of ventricular
end-systolic and end-diastolic volumes in T-MDS group
were significantly higher than NT-MDS and controls
(p <0.05 and p <0.04 respectively). The left atrial
volume indexed (LAV index) was significantly larger in
patients of T-MDS group than NT-MDS and controls
(35.9 ± 15 mL/m2, 26.6 ± 5,2 mL/m2, 22.8 ± 8 mL/m2 re-
spectively) (p <0.004.). A strong correlation between
hemoglobin levels and LVEDV (left ventricular end-
diastolic volume), LVESV (left ventricular end-systolic
volume), LAV (left atrial volume) and LAV index was
observed, with r values of −0.4, -0.4, -0.53 and 0.51
respectively (p <0.02, p <0.02, p <0.002 and p <0.002
respectively). See Figure 1. Otherwise, we found no
correlation between ferritin levels and echocardio-
graphic parameters.
The reduction of blood viscosity in severe anemia
increases blood return [4] and ventricular preload
which lead to atrial and ventricular enlargementral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients were diagnosed and classified according to WHO, IPSS and WPSS criteria
Patient WHO IPSS Serum Ferritin Transfusion therapy Transfusional dependent WPSS
1 RA NA 288,8 No transfusion therapy NO NA
2 RAEB 2 INT 1 94,7 No transfusion therapy NO HIGH
3 RCMD INT 1 416,5 14 RCC NO LOW
4 RARS INT 1 1.994,0 69 RCC Yes LOW
5 RA NA 826,0 No transfusion therapy NO NA
6 RA LOW 22,4 No transfusion therapy NO LOW
7 MDS-T NA 3.484,0 42 RCC Yes NA
8 RARS NA 1.399,0 64 RCC Yes NA
9 RCMD NA 7.107,0 81 RCC Yes NA
10 RARS LOW 1.587,0 20 RCC Yes LOW
11 RARS INT 1 132,0 04 RCC NO INT
12 RARS LOW 1.937,8 82 RCC Yes LOW
13 RARS NA 541,0 No transfusion therapy NO NA
14 RA LOW 307,0 No transfusion therapy NO VERY LOW
15 RCMD INT 1 5.113,1 96 RCC Yes INT
16 RCMD LOW 38,0 No transfusion therapy NO LOW
17 RCMD NA 98,0 03 RCC NO NA
18 RARS LOW 318,0 No transfusion therapy NO VERY LOW
19 RCMD LOW 87,0 No transfusion therapy NO LOW
20 RCMD NA 765,0 38 RCC Yes NA
21 RCMD INT 1 780,0 17 RCC Yes HIGH
22 RARS LOW 356,2 No transfusion therapy NO VERY LOW
23 RCMD INT 1 298,4 No transfusion therapy NO LOW
24 RCMD INT 1 2.160,0 24 RCC Yes HIGH
25 RA LOW 86,4 No transfusion therapy NO VERY LOW
26 RCMD NA 276,0 No transfusion therapy NO NA
27 RCMD NA 1.922,3 24 RCC Yes NA
28 RAEB 2 INT 2 1.022,0 42 RCC Yes VERY HIGH
29 RARS NA 321,0 No transfusion therapy NO NA
30 RCMD NA 223,0 12 RCC Yes NA
31 RAEB 1 INT 1 229,0 03 RCC NO VERY LOW
32 RCMD INT 1 132,4 No transfusion therapy NO INT
33 RCMD NA 556,0 04 RCC NO NA
34 RCMD NA 850,0 10 RCC NO NA
Legend. MDS unclassifiable; RA, refractory anemia; RAEB, RA with excess of blasts; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage
dysplasia; t-MDS, therapy-related MDS; WHO, World Health Organization. red cell concentrate – RCC. NA -Not applicable, due to cytogenetics
by G-banding without metaphases).
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Table 2 Echocardiographic parameters of patients and controls
Controls(14) NT-MDS(21) T-MDS(13) P value
Baseline demographics and characteristics
Age (year) 72.4 ± 8 (58–84) 70.3 ± 14 (47–88) 65.2 ± 20 (27–90) NS
Gender (m/f ) (6/8) (7/14) (6/7)
Body weigth (kg) 66.0 ± 11.9 (46 – 83) 63.7 ± 10.1 (43.6 – 91.3) 64.9 ± 10.1 (49.3 – 90) NS
Height (m) 1.59 ± 0.09 (1.45 – 1.75) 1.57 ± 0.07 (1.46 – 1.72) 1.59 ± 0.08 (1.45 – 1.70) NS
BSA (m2) 1.68 ± 0.16 (1.42 – 1.98) 1.64 ± 0.15 (1.33 – 2.01) 1.67 ± 0.15 (1.4 – 2.01) NS
BMI (kg/m2) 26.2 ± 5.7 (19.1 – 36.9) 25.8 ± 2.9 (20.5 – 32.3) 25.5 ± 3.7 (21.4 – 32.7) NS
HR (bpm) 75.8 ± 5.4 (66–83) 77.6 ± 1.4 (66–88) 78.4 ± 2.2(65–90) NS
SBP (mmHg) 139.2 ± 19 (110–180) 121.8 ± 16 (100–150) <0.02
DBP (mmHg) 77.9 ± 12 (60–108) 70 ± 9.6 (60–90) NS
Hb (g/dL) 9.85 ± 1.8 (6.6 - 12.7) 6.5 ± 1.7 (3.8 - 9.9) <0.001
Ferritin (ng/mL) 298.8 ± 234 (22.4 a 850) 2269 ± 1931 (223 a 7101) <0.001
Chamber quantification and ejection fraction of patients and controls
LVDD (mm) 46.0 ± 4.7 (40–57) 48.5 ± 3.9 (41–56) 49.3 ± 6.6 (40–64) NS
LVSD (mm) 26.9 ± 4.9 (19–39) 27.7 ± 3.7 (22–37) 29.5 ± 6.8 (23–50) NS
IVS (mm) 8.9 ± 2.3 (6–16) 8.5 ± 0.9 (7–11) 8.9 ± 1.4 (7–12) NS
LVPW (mm) 8.5 ± 1.7 (6–13) 8.4 ± 0.7 (7–10) 8.8 ± 1.4 (7–12) NS
MASS (g) 165.9 ± 61,0 (79–326) 173.8 ± 34.1 (116–249) 165.9 ± 61.0 (90–321) NS
MASS index (g/m2) 101.3 ± 37 (55.6 - 185) 106 ± 18 (73–140.7) 110 ± 37.1 (56.2 - 198) NS
EF%TEI 71.8 ± 7.6 (58.2 - 89) 71.9 ± 6.5 (58.8 - 80.1) 69.8 ± 9.3 (43.6 - 83.9) NS
FS (%) 41.4 ± 6.8 (31.2 - 58) 41.6 ± 5.7 (31–48.7) 39.4 ± 7.2 (22–53) NS
LA (mm) 32 ± 4.2 (27–44) 33.4 ± 4.2 (28–43) 36.5 ± 4.9 (31–46) <0.04*
EF%SIM 67.7 ± 7.3 (50.1 - 81.3) 66.2 ± 4.8 (55.2 - 76.1) 64.7 ± 5.4 (50.7 - 70.8) NS
LVEDV (ml) 65.5 ± 18 (37–105) 85.1 ± 29.9 (44–169) 92.8 ± 36.1 (49–189) <0.05*
LVESV (ml) 20.5 ± 6.2 (10–28) 28.7 ± 11.9 (12.5 - 65) 33.8 ± 19.7 (15–93) <0.04*
LAV (ml) 39.1 ± 14.5 (17–69) 43.5 ± 10.3 (25–64) 59.8 ± 24.8 (29–120) <0.006**
LAV index (mL/m2) 22.8 ± 8 (10.5 - 39.6) 26.5 ± 5.2 (15.9 - 34.8) 35.9 ± 15 (18.8 - 70.9) <0.004**
Doppler parameters (transmitral and myocardial tissue) and strain of patients and controls
Evel(cm/s) 77.2 ± 13.2 (55.4 - 105) 89.6 ± 20 (63–128) 96.6 ± 14.2 (68.5 - 116) <0.02*
Avel(cm/s) 94.3 ± 18 (68.6 - 137.3) 100.2 ± 19 (68.5 - 131) 100.6 ± 27 (52.8 - 145) NS
E/A 0.83 ± 0.2 (0.6 - 1.2) 0.9 ± 0.2 (0.6 - 1.4) 1.0 ± 0.26 (0.64 - 1,6) NS
Em(cm/s) 8.6 ± 3.2 (4.1 - 14) 9.3 ± 2.4 (5.4 - 14) 10.4 ± 2.5 (7.5 a 14.8) NS
E/Em 10 ± 3.4 (5.3 - 16.2) 10.3 ± 3,9 (5.6 - 20) 9.7 ± 2.9 (5.9 - 14.4) NS
LV-Sm(cm/s) 6.5 ± 1.3 (5.1 - 9.5) 7.9 ± 1.3 (5.5 - 10.8) 7.8 ± 1.3 (6–10,3) <0.02*
RV-Sm(cm/s) 10.1 ± 0.7 (9.1 - 11) 11.4 ± 3.3 (7.6 - 19) 12.3 ± 1,5 (9.8 - 14,7) NS
TAPSE(mm) 24.9 ± 4.2 (20–33) 28.2 ± 5.3 (21–39) 28.9 ± 5 (22–40) NS
VD basal(mm) 30.1 ± 6.4 (22–48) 31.7 ± 4 (24–41) 31.5 ± 4 (23–39) NS
ST2DL (%) −19.9 ± 2.7 (−24 to −13) −20.7 ± 2.5 (−25 to −16,8) −20.9 ± 1.4 (−23 to - 18,6) NS
Legend. NT-MDS: non-transfused patients; T-MDS: transfused patients; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; IVS:
inter-ventricular septum; LVPW: left ventricular posterior wall; MASS: left ventricular mass; EF%TEI: ejection fraction Teicholz; FS: fractional shortening; LA: left atrial
diameter; EF%SIM: ejection fraction Simpson; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LAV: left atrial volume.
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Figure 1 Linear correlation between left cardiac volumes and values of hemoglobin. A. LAV: left atrial volume. B. LVEDV: left ventricular
end-diastolic volume; C. LAV index : left atrial volume index. D. LVESV: left ventricular end-systolic volume.
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esis, these results are correlated to hemoglobin levels.
The T-MDS group showed no clinical sign of cardiac
dysfunction. Otherwise, cardiac alterations were detected
by tissue-doppler echocardiography, a relative fast and
cheap bedside method to evaluate heart function. Echo-
cardiography should be routinely performed in MDS
patients to detect preclinical cardiac alterations and pre-
vent more heart insults in these group of chronic anemic
aged patients.
Abbreviation
NT-MDS: Non-transfused patients; T-MDS: Transfused patients; LVDD: Left
ventricular diastolic diameter; LVSD: Left ventricular systolic diameter;
IVS: Inter-ventricular septum; LVPW: Left ventricular posterior wall; LVEDV: Left
ventricular end-diastolic volume; LVESV: Left ventricular end-systolic volume;
LAV: Left atrial volume; RCC: Red cell concentrate; VD: Ventricular dysfunction.
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